Our Company
Press Release Archive
-
Johnson & Johnson Releases 2016 Health for Humanity Report
-
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
-
Douglas Wallace, Ph.D., Wins 2017 Dr. Paul Janssen Award for Biomedical ResearchJohnson & Johnson Launches Campaign for Champions of Science
-
DARZALEX® (daratumumab) Approved by the U.S. FDA in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Who Have Received At Least Two Prior TherapiesDARZALEX combination therapy offers new option for patients previously treated with two commonly used treatments (lenalidomide and a proteasome inhibitor)
-
Johnson & Johnson Announces Completion of Acquisition of ActelionTransaction Expands Janssen Portfolio with Leading Differentiated In-Market Medicines and Promising Late-Stage Therapies
-
New Phase 3 Data Show Anti-TNF Alpha SIMPONI ARIA® (golimumab) Significantly Improved Arthritis And Skin Manifestations In Patients With Active Psoriatic ArthritisTreatment with SIMPONI ARIA® Showed Significant Inhibition in the Progression of Structural Damage
-
Pimodivir Alone or in Combination with Oseltamivir Demonstrated a Significant Reduction in Viral Load in Adults with Influenza A- Phase 2b results presented at the 5th International Society for Influenza and Respiratory Diseases Antiviral Group (ISIRV-AVG) Conference -
-
Johnson & Johnson Medical Devices Companies Bring Real-World Evidence to Infection Risk Management to Help Medical University of South Carolina Reduce Infection Risk in the ORCareAdvantage from the Johnson & Johnson Medical Devices Companies Help Health Systems Address Risks Related to Healthcare-Associated Infections
-
INVOKANA® (canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction and Stroke in the CANVAS ProgramStudy results published in the New England Journal of Medicine and featured in a special symposium at the American Diabetes Association 77th Scientific Sessions
-
Johnson & Johnson Announces Expected Settlement of Actelion Tender Offer on June 16, 2017Announces Receipt of All Regulatory Approvals Required to Complete Acquisition of Actelion